Business Context and Reporting Period
This Form 8-K Current Report was filed by Bone Biologics Corp. on November 24, 2014. The filing discloses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the compensation package for the newly appointed director.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven members.
- New Appointment: George A. Oram was appointed as a director and to the Compensation Committee to fill the newly created vacancy.
- Compensation Structure: Mr. Oram's compensation includes:
- Annual cash retainer of $25,000, paid quarterly.
- Stock options to purchase 50,000 shares at $1.00 per share, exercisable after one year of service with a 10-year term.
- Annual stock grants valued at $50,000, issued in four quarterly installments of $12,500 each, valued based on the 10-day average trading price prior to issuance.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, guidance, risks, contingencies, or unusual items. The document is strictly limited to the disclosure of the director appointment and associated compensatory arrangements.
Investor Verification Checklist
- Verify the current share price to assess the value of the quarterly stock grants and the exercise price of the options.
- Review the attached Exhibit 10.1 (Director Offer Letter) for complete terms and conditions not summarized in the 8-K.
- Confirm the impact of the new board member's background in healthcare and biotechnology on the company's strategic direction.
- Check subsequent filings (10-Q or 10-K) for the actual issuance of the quarterly stock grants.